**Figure 2.** (**A**) The smooth estimate of HR for relapse among high-risk ccRCC patients treated with adjuvant sunitinib or placebo. (**B**) Conditional probability of surviving an additional 3 disease-free year at various time points in very high-risk (T3, Fuhrman grade 2, ECOG Performance Status≥1; or T4 or N1) and high-risk group. The dots represent the probability point estimates, and the vertical bars represent the 95% CIs of the corresponding point estimates.